Date: 2013-05-01
Type of information: Licensing agreement
Compound: alvocidib (flavopiridol)
Company: Tolero Pharmaceuticals (USA - UT) Sanofi (France)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: kinase inhibitor. Alvocidib is a small molecule inhibitor of the cyclin-dependent kinases that has demonstrated activity in clinical trials in several malignancies, including chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).
Disease:
Details: * On May 1, 2013, Tolero Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of novel therapeutics to treat cancer and other serious human diseases, announced that it has entered into a license agreement with Sanofi in which it received exclusive worldwide rights to develop and commercialize alvocidib (flavopiridol).
Financial terms: Under the terms of the agreement, Tolero Pharmaceuticals will pay Sanofi an undisclosed upfront payment, and future payments on the successful achievement of milestones related to the commercialization of alvocidib. Sanofi will also receive tiered royalties on sales of alvocidib and maintains certain negotiation rights with respect to manufacturing the pharmaceutical product forTolero and becoming a commercialization partner.
Latest news:
